Apyx Medical (NASDAQ:APYX) Posts Earnings Results, Beats Expectations By $0.01 EPS

Apyx Medical (NASDAQ:APYX) announced its earnings results on Thursday. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01, FiscalAI reports. The business had revenue of $13.88 million during the quarter, compared to the consensus estimate of $13.18 million. Apyx Medical had a negative return on equity of 76.18% and a negative net margin of 14.78%.

Here are the key takeaways from Apyx Medical’s conference call:

• Second-quarter revenue rose 22% to $13.9 million, led by a 28% increase in surgical aesthetics sales to $12.4 million. Management attributed the growth to AYON adoption, higher international generator sales, and increased domestic single-use handpiece volume.
• AYON received FDA clearance for power-assisted liposuction, with initial shipments beginning in June and a broader commercial launch planned for the third quarter. Management said early surgeon feedback was “exceptional” and expects more than 95% of new AYON customers to include the PowerLipo attachment.
• Management highlighted clinical studies supporting Renuvion’s role in body contouring, including higher patient satisfaction and fewer abdominoplasty or revision procedures when combined with liposuction, while maintaining comparable complication rates.
• Profitability improved, with gross margin rising to 63.9%, operating loss narrowing to $1.8 million, and adjusted EBITDA loss improving to $0.7 million. However, operating cash use increased to $3.5 million, and the company ended the quarter with $27.6 million in cash.
• The company reaffirmed 2026 revenue guidance of $59 million to $60 million and expects OEM revenue to decline to approximately $5 million from $7.5 million in 2025. Tariffs are also pressuring margins, although potential tariff refunds are not included in current guidance.

Apyx Medical Price Performance

Shares of NASDAQ APYX traded down $0.11 during midday trading on Friday, hitting $4.05. The stock had a trading volume of 299,178 shares, compared to its average volume of 64,993. The company has a market capitalization of $169.74 million, a PE ratio of -20.25 and a beta of 1.39. The stock has a 50 day simple moving average of $4.24 and a 200-day simple moving average of $3.94. Apyx Medical has a 1 year low of $1.70 and a 1 year high of $5.08. The company has a quick ratio of 4.79, a current ratio of 5.80 and a debt-to-equity ratio of 2.68.

Institutional Trading of Apyx Medical

Large investors have recently made changes to their positions in the company. State Street Corp increased its holdings in shares of Apyx Medical by 6.8% in the fourth quarter. State Street Corp now owns 116,706 shares of the company’s stock valued at $408,000 after purchasing an additional 7,400 shares during the last quarter. Geode Capital Management LLC boosted its stake in Apyx Medical by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 358,829 shares of the company’s stock worth $1,257,000 after buying an additional 7,551 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Apyx Medical in the 3rd quarter valued at $28,000. Hudson Bay Capital Management LP purchased a new stake in shares of Apyx Medical in the fourth quarter valued at about $73,000. Finally, Osaic Holdings Inc. purchased a new stake in shares of Apyx Medical in the second quarter valued at about $50,000. 55.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Zacks Research raised shares of Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th. HC Wainwright started coverage on shares of Apyx Medical in a report on Monday, July 13th. They set a “buy” rating and a $7.00 price objective on the stock. Wall Street Zen lowered shares of Apyx Medical from a “buy” rating to a “hold” rating in a research report on Sunday, April 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a research report on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Apyx Medical presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.60.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.